DePuy Orthopaedics alerted doctors to a high early failure rate of its artificial hip after announcing it would phase out the device citing slow sales.
Beta amyloid, which was once thought to be a chief villain in Alzheimer’s, may be part of the brain’s normal defenses, researchers at Harvard suggested.
Researchers have tested the Sensecam, which contains a digital camera and an accelerometer, as an aid to people with Alzheimer’s disease and other memory disorders.
A new study found that older people hospitalized for a critical condition had a statistically significant drop in scores on cognitive tests when compared with people who had not been hospitalized.
Dr. Childs helped shape the understanding of inherited diseases as scientists learned more about so-called inborn errors of metabolism, biochemistry and molecular biology.
A small, underfunded hospital in Arizona, with about 500 births a year, is outperforming richer institutions when it comes to keeping Caesarean rates down.
The drug, called Dimebon, failed in its first late-stage clinical trial, dealing a blow to patients with Alzheimer’s and the companies developing the treatment, Medivation and Pfizer.
Seeking support for an overhaul, the administration is pointing to a Goldman Sachs study suggesting investors buy insurance shares because rates are up and competition is down.
President Obama met with insurance executives and selected House Democrats, as party leaders struggled to figure out whether they can meet his timetable.
Dr. Peter J. Pronovost, medical director of the Quality and Safety Research Group at Johns Hopkins Hospital in Baltimore, travels the country advising hospitals on innovative safety measures.
